Dr. Rachel Tate uptoTate
3 years 5 months ago
JAKi cycling, likely something we all do/consider in clinic. Dr. S. Cohen reviews the JAK-pot study which shows good, expected results between cycling in patients. #RNL2023 @RheumNow https://t.co/qBau79o0VQ
Dr. Rachel Tate uptoTate
3 years 5 months ago
#RNL2023 is up and running! Join us online! @RheumNow https://t.co/AGbpEjXSh6
Eric Dein ericdeinmd
3 years 5 months ago
Follow me today and tomorrow for @RheumNow Live 2023 Coverage!
#RheumTwitter #RNL2023 https://t.co/sS6AoF1Dij
Dr. John Cush RheumNow
3 years 5 months ago
QD Clinic - RheumNow Live 2023 Preview https://t.co/T8VMyrL1Qz https://t.co/E90wsaqwaY
Dr. John Cush RheumNow
3 years 5 months ago
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/sax8iHuljb https://t.co/71zqAzZViV
Dr. John Cush RheumNow
3 years 5 months ago
Itaconate - A Potential New Immunosuppressive
Researchers have revealed the modulatory effect of the anti-inflammatory metabolite ITA on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.
https://t.co/1kaxHou8pz https://t.co/VLLAzgiYoM
Dr. John Cush RheumNow
3 years 5 months ago
Happy Match Day! Congratulations to all that have matched. #MATCHDAY2023
Eric Dein ericdeinmd
3 years 5 months ago
Follow my coverage tomorrow and Sunday!
#RNL2023 RheumNow Live
@RheumNow #RheumTwitter https://t.co/6cZHJxPltA
Dr. John Cush RheumNow
3 years 5 months ago
Multicenter study of 1516 MIS-C pts - Initial Rx: 13% recv anakinra (w/ or w/o) otherdrugs; 64% rx w/ IVIG & steroids, 16%IVIG alone, 4% steroids alone. Anakinra gave no short-term CV benefits over IVIG and glucocorticoids alone. https://t.co/IVaC5dXzs8
Dr. John Cush RheumNow
3 years 5 months ago
28 biomarkers studied in 259 SSc-ILD, 179 SSc-NO ILD, 172 IPF & 30 healthy controls. Composite biomarker index (w/ SP-D [surfactant prot. D], Ca15-3 [MUC1], & ICAM-1) strongly correlated w/ SSc-ILD (adj OR 12.7); independent of age, sex, smoking, PFTs https://t.co/F0iKFqcZoY https://t.co/Ao25N1DFIx
This week on the podcast, Dr. Jack Cush recalls what life was like early on during COVID, from March to June of 2020. During this time, his close friend, Larry, contracted COVID-19 and was hospitalized, intubated and put on mechanical ventilation for nearly 2 months.
Dr. John Cush RheumNow
3 years 5 months ago
Transcriptomic studies of Rx Refractory #RA pts shows increased gene expression of plasmacytoid dendritic cells (pDC) (reflecting expansion of pDC precursors) correlated well w/ Rx resistance. Type I IFN negatively correlated w pre-DC gene expression https://t.co/japvTnuTNu https://t.co/ad6ofbg3cO
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
AAV recommendations were last published in 2016, and since, research and clinical trials have advanced our understanding of AAV. A EULAR task force of 20 experts from 16 countries, reviewed the literature and developed four overarching principles and 17 recommendations.
